Aytu BioPharma (AYTU) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Circular Clean Climate Contaminant Environment Environmental Forest Green Lifecycle Materials Mineral Nature Offset Oil Package Packaging Pandemic Pollutant Raw Materials Toxic Waste Water Wind Access Affordability Attrition Benefits Black Community Culture Customer Cyber Data Security Death Demographic Disability Diversity Drug Pricing Employee Endanger Engagement Gender Health and Safety Health Care Healthcare Hire Human Capital Human Resources Incident Injuries Injury Opioid Privacy Product Safety Recall Recruit Recruitment Reimbursement Retention Safety Satisfaction Skill Skilled Skills Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Workplace Safety Assessment Assurance Attorneys General Audit Bonus Chronic Class Action Lawsuit Classified Commitment Conflict of Interest Controversy Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Plaintiff Pledging Procurement Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Special Meeting Stewardship Strategy Sustainability Targets Tax Transparency

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The 2022 annual meeting of stockholders for Aytu BioPharma, Inc. was held on May 18, 2022 (the “2022 Annual Meeting”). Of the 33,355,935 shares outstanding on the record date for the meeting, a total of 20,034,954 shares were present or represented at the meeting. The matters voted on and the results of the votes at the 2022 Annual Meeting are as follows:

Our stockholders elected five members to our board of directors as follows:

	Number of Votes Cast For	Number of Votes Withheld	Number of Broker Non-Votes

Members
Joshua R. Disbrow	7,950,490	3,552,901	8,531,563
Gary V. Cantrell	7,694,480	3,808,911	8,531,563
Carl C. Dockery	7,512,820	3,990,571	8,531,563
John A. Donofrio, Jr.	7,684,806	3,818,585	8,531,563
Michael E. Macaluso	8,029,799	3,473,592	8,531,563

The ratification of the appointment of Plante & Moran, PLLC as the Company's independent registered public accounting firm for the fiscal year ending June 30, 2022 was approved with 16,596,117 votes in favor, 2,811,766 votes against and 627,071 abstentions.

The advisory vote on executive compensation was approved with 7,386,646 votes in favor, 3,985,791 votes against and 130,954 abstentions. There were 8,531,563 broker non-votes.

The advisory vote on the frequency with which future advisory votes on executive compensation should be held was had 5,841,439 votes for one year, 95,286 votes for two years, 5,309,518 votes for three years and 257,148 abstentions.

In light of these results, notwithstanding its previous recommendation in the proxy statement for the 2022 Annual Meeting, the Company’s Board of Directors determined that the Company will hold future Say-on-Pay votes on an annual basis until the occurrence of the next advisory vote on the frequency of Say-on-Pay votes. The next advisory vote regarding the frequency of Say-on-Pay votes is required to occur no later than the Company’s 2028 Annual Meeting of Stockholders.